Archive | February, 2016
PM 1a

Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy

 2016 Feb 29. pii: 201600251. [Epub ahead of print] Palma E1, Reyes-Ruiz JM2, Lopergolo D3, Roseti C4, Bertollini C5, Ruffolo G5, Cifelli P6, Onesti E3, Limatola C7, Miledi R8, Inghilleri M3. Author information Abstract Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting motor neurons that leads to progressive paralysis of skeletal muscle. Studies of ALS have revealed defects in expression of acetylcholine receptors (AChRs) […]

PM 1a

Tetrahydrobiopterin attenuates DSS-evoked colitis in mice by rebalancing redox and lipid signaling.

 2016 Feb 29. pii: jjw056. [Epub ahead of print] Zschiebsch K1, Fischer C1, Pickert G1, Häeussler A1, Radeke H2, Grösch S1, Ferreirós N1, Geisslinger G1, Werner ER3, Tegeder I4. Author information Abstract BACKGROUND AND AIMS: GTP cyclohydrolase (GCH1) governs the production of the enzyme cofactor, tetrahydrobiopterin (BH4), which is essential for biogenic amine synthesis, lipid metabolism via alkylglycerol monooxygenase (AGMO) and redox coupling of […]

PM 1a

Nabilone for the Management of Pain.

2016 Feb 29. doi: 10.1002/phar.1709. [Epub ahead of print] Tsang CC1, Giudice MG1. Author information Abstract Nabilone, a synthetic cannabinoid, is approved in many countries including, but not limited to, Canada, the United States, Mexico, and the United Kingdom for the treatment of severe nausea and vomiting associated with chemotherapy. Clinical evidence is emerging for its […]

PM 1a

Involvement of TRPV1 channels in the activity of the cannabinoid WIN 55,212-2 in an acute rat model of temporal lobe epilepsy.

2016 Feb 27;122:56-65. doi: 10.1016/j.eplepsyres.2016.02.005. [Epub ahead of print] Carletti F1, Gambino G2, Rizzo V3, Ferraro G4, Sardo P5. Author information Abstract The exogenous cannabinoid agonist WIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-Yl]-1-naphthalenylmethanone (WIN), has revealed to play a role on modulating the hyperexcitability phenomena in the hippocampus. Cannabinoid-mediated mechanisms of neuroprotection have recently been found to imply the modulation of transient receptor potential vanilloid […]

New England thumb

Marijuana Tourism and Emergency Department Visits in Colorado

CORRESPONDENCE N Engl J Med 2016; 374:797-798February 25, 2016DOI: 10.1056/NEJMc1515009 Article Metrics To the Editor: The liberalization of marijuana policy in Colorado was a stepwise process; voters approved the legalization of medical marijuana in 2000, medical licensure and use increased in 2009, voters approved the legalization of retail marijuana in 2012, and retail sales began […]

PM 1a

Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

2016 Feb 24. [Epub ahead of print] Zlebnik NE1, Cheer JF2. Author information Abstract The Cannabis sativa plant has been used to treat various physiological and psychiatric conditions for millennia. Current research is focused on isolating potentially therapeutic chemical constituents from the plant for use in the treatment of many central nervous system disorders. Of particular […]

PM 1a

Involvement of Central Endothelin ETA and Cannabinoid CB1 Receptors and Arginine Vasopressin Release in Sepsis Induced by Cecal Ligation and Puncture in Rats.

 2016 Feb 24. [Epub ahead of print]Leite MC1, Lomba LA, Bastos-Pereira AL, Brito HO, Fraga D, Zampronio AR. Author information Abstract We previously reported that endothelin-1 (ET-1) reduced the frequency of spontaneous excitatory currents in vasopressinergic magnocellular cells through the activation of endothelin ETA receptors in rat brain slices. This effect was abolished by a cannabinoid CB1 receptor antagonist, suggesting the involvement […]

PM 1a

Endocannabinoids in the Gut.

 2016 Feb;1(1):67-77. Epub 2016 Feb 24. DiPatrizio NV. Abstract Cannabis has been used medicinally for centuries to treat a variety of disorders, including those associated with the gastrointestinal tract. The discovery of our bodies’ own “cannabis-like molecules” and associated receptors and metabolic machinery – collectively called the endocannabinoid system – enabled investigations into the physiological […]

PM 1a

Comparison of outcome expectancies for synthetic cannabinoids and botanical marijuana.

2016 Feb 24:1-8. [Epub ahead of print] Lauritsen KJ1, Rosenberg H1. Author information Abstract BACKGROUND: Although initially developed for medical purposes, synthetic cannabinoids have also been consumed for recreational purposes. OBJECTIVE: To evaluate whether agreement with positive and negative outcome expectancies differed for synthetic cannabinoids versus botanical marijuana, and assess reported reasons for using synthetic cannabinoids. METHOD: Using a web-based recruitment […]